Laurence W Busse

List of Publications by Year
in descending order

46	3,082	394421	345221
papers	citations	19 h-index	36 g-index

47	47	47	2791
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Protection of Messenger RNA Vaccines Against Hospitalized Coronavirus Disease 2019 in Adults Over the First Year Following Authorization in the United States. Clinical Infectious Diseases, 2023, 76, e460-e468.	5.8	9
2	Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines for Preventing Coronavirus Disease 2019 Hospitalizations in the United States. Clinical Infectious Diseases, 2022, 74, 1515-1524.	5.8	144
3	Effectiveness of mRNA Vaccines Against COVID-19 Hospitalization by Age and Chronic Medical Conditions Burden Among Immunocompetent US Adults, March-August 2021. Journal of Infectious Diseases, 2022, 225, 1694-1700.	4.0	14
4	Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ, The, 2022, 376, e069761.	6.0	393
5	mRNA Vaccine Effectiveness Against Coronavirus Disease 2019 Hospitalization Among Solid Organ Transplant Recipients. Journal of Infectious Diseases, 2022, 226, 797-807.	4.0	25
6	1500: ANGIOTENSIN II FOR DISTRIBUTIVE SHOCK IN PATIENTS WITH DURABLE LEFT VENTRICULAR ASSIST DEVICES. Critical Care Medicine, 2022, 50, 754-754.	0.9	0
7	441: THE EFFECT OF ANGIOTENSIN II IN VENOVENOUS VERSUS VENOARTERIAL EXTRACORPOREAL MEMBRANE OXYGENATION. Critical Care Medicine, 2022, 50, 210-210.	0.9	0
8	Protocol Compliance Guiding Angiotensin II Use in Post Cardiovascular Surgery Vasoplegia. , 2022, 4, e0687.		3
9	Effectiveness of the Ad26.COV2.S (Johnson & Johnson) Coronavirus Disease 2019 (COVID-19) Vaccine for Preventing COVID-19 Hospitalizations and Progression to High Disease Severity in the United States. Clinical Infectious Diseases, 2022, 75, S159-S166.	5.8	13
10	Effect of Vitamin C, Thiamine, and Hydrocortisone on Ventilator- and Vasopressor-Free Days in Patients With Sepsis. JAMA - Journal of the American Medical Association, 2021, 325, 742.	7.4	168
11	1104: Improvement in Protocol Compliance Through a Comprehensive Plan Guiding Angiotensin II Use. Critical Care Medicine, 2021, 49, 553-553.	0.9	0
12	39: Improvement in Mortality Linked to Protocol Compliance Guiding Angiotensin II Use. Critical Care Medicine, 2021, 49, 20-20.	0.9	0
13	1276: Decrease in Mortality With Protocol Compliance in Angiotensin II Use in the Cardiovascular ICU. Critical Care Medicine, 2021, 49, 644-644.	0.9	0
14	Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity. JAMA - Journal of the American Medical Association, 2021, 326, 2043.	7.4	458
15	New strategies to optimize renal haemodynamics. Current Opinion in Critical Care, 2020, 26, 536-542.	3.2	14
16	115: TRANSITION FROM HOSPITALIST-MANAGED TO INTENSIVIST-MANAGED COMMUNITY ICU. Critical Care Medicine, 2020, 48, 40-40.	0.9	0
17	Angiotensin II for the treatment of distributive shock in the intensive care unit: A US cost-effectiveness analysis. International Journal of Technology Assessment in Health Care, 2020, 36, 145-151.	0.5	10
18	Renin and Survival in Patients Given Angiotensin II for Catecholamine-Resistant Vasodilatory Shock. A Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1253-1261.	5.6	101

#	Article	IF	Citations
19	Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock. Critical Care, 2020, 24, 43.	5.8	69
20	1708: EVALUATION OF HYDROXOCOBALAMIN COMPARED TO METHYLENE BLUE FOR VASOPLEGIA POST-CARDIOTHORACIC SURGERY. Critical Care Medicine, 2020, 48, 829-829.	0.9	0
21	COVID-19 and the RAASâ€"a potential role for angiotensin II?. Critical Care, 2020, 24, 136.	5.8	84
22	In response: Letter on update to the Vitamin C, Thiamine and Steroids in Sepsis (VICTAS) protocol. Trials, 2020, 21, 351.	1.6	1
23	Vasoplegic syndrome following cardiothoracic surgeryâ€"review of pathophysiology and update of treatment options. Critical Care, 2020, 24, 36.	5.8	97
24	Successful Treatment of Antihypertensive Overdose Using Intravenous Angiotensin II. Journal of Emergency Medicine, 2019, 57, 339-344.	0.7	10
25	Vasopressor Therapy and Blood Pressure Management in the Setting of Acute Kidney Injury. Seminars in Nephrology, 2019, 39, 462-472.	1.6	22
26	Sensitivity to angiotensin II dose in patients with vasodilatory shock: a prespecified analysis of the ATHOS-3 trial. Annals of Intensive Care, 2019, 9, 63.	4.6	36
27	Angiotensin II in Vasodilatory Shock. Critical Care Clinics, 2019, 35, 229-245.	2.6	12
28	The Vitamin C, Thiamine and Steroids in Sepsis (VICTAS) Protocol: a prospective, multi-center, double-blind, adaptive sample size, randomized, placebo-controlled, clinical trial. Trials, 2019, 20, 197.	1.6	57
29	Response. Chest, 2019, 155, 242-243.	0.8	2
30	Sepsis Updates: Unpackaging the New Bundles. International Anesthesiology Clinics, 2019, 57, 3-16.	0.8	2
31	Angiotensin II. Critical Care Medicine, 2019, 47, e436.	0.9	3
32	Just a Little Off the Top, Please*. Critical Care Medicine, 2019, 47, 1810-1813.	0.9	0
33	Update to the Vitamin C, Thiamine and Steroids in Sepsis (VICTAS) protocol: statistical analysis plan for a prospective, multicenter, double-blind, adaptive sample size, randomized, placebo-controlled, clinical trial. Trials, 2019, 20, 670.	1.6	7
34	Regional differences in the treatment of refractory vasodilatory shock using Angiotensin II in High Output Shock (ATHOS-3) data. Journal of Critical Care, 2019, 50, 188-194.	2.2	10
35	Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II. Critical Care Medicine, 2018, 46, 949-957.	0.9	186
36	Management of Refractory Vasodilatory Shock. Chest, 2018, 154, 416-426.	0.8	157

#	Article	IF	Citations
37	Angiotensin in Critical Care. Critical Care, 2018, 22, 69.	5.8	46
38	Angiotensin II: a new therapeutic option for vasodilatory shock. Therapeutics and Clinical Risk Management, 2018, Volume 14, 1287-1298.	2.0	21
39	Clinical Experience With IV Angiotensin II Administration: A Systematic Review of Safety. Critical Care Medicine, 2017, 45, 1285-1294.	0.9	52
40	Angiotensin II for the Treatment of Vasodilatory Shock. New England Journal of Medicine, 2017, 377, 419-430.	27.0	591
41	The effect of angiotensin II on blood pressure in patients with circulatory shock: a structured review of the literature. Critical Care, 2017, 21, 324.	5.8	44
42	The use of angiotensin II in distributive shock. Critical Care, 2016, 20, 137.	5.8	26
43	Side Effects and Adverse Events Associated With Intravenous Angiotensin II in Humans: A Systematic Review and Meta-analysis. Chest, 2015, 148, 348A.	0.8	0
44	Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study. Critical Care, 2014, 18, 534.	5.8	138
45	Submassive Pulmonary Embolism. Critical Care Clinics, 2014, 30, 447-473.	2.6	19
46	Minding the Gap: A Comparison of the Albumin-Lactate-Phosphate Corrected Anion Gap (ALPCAG) to the Strong Ion Gap (SIG). Chest, 2011, 140, 1012A.	0.8	1